Clinical Trial Update: Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

View source ↗

Summary

An upcoming clinical trial is evaluating ovarian toxicity outcomes in patients with triple-negative breast cancer treated with immunotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Triple Negative Breast Cancer (TNBC) | Status: NOT_YET_RECRUITING